A citation-based method for searching scientific literature

Alesha A Thai, Benjamin J Solomon, Lecia V Sequist, Justin F Gainor, Rebecca S Heist. Lancet 2021
Times Cited: 55







List of co-cited articles
110 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
Hyuna Sung, Jacques Ferlay, Rebecca L Siegel, Mathieu Laversanne, Isabelle Soerjomataram, Ahmedin Jemal, Freddie Bray. CA Cancer J Clin 2021
29

Cancer Statistics, 2021.
Rebecca L Siegel, Kimberly D Miller, Hannah E Fuchs, Ahmedin Jemal. CA Cancer J Clin 2021
14

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
9

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
Martin Reck, Delvys Rodríguez-Abreu, Andrew G Robinson, Rina Hui, Tibor Csőszi, Andrea Fülöp, Maya Gottfried, Nir Peled, Ali Tafreshi, Sinead Cuffe,[...]. N Engl J Med 2016
7

Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.
Leena Gandhi, Delvys Rodríguez-Abreu, Shirish Gadgeel, Emilio Esteban, Enriqueta Felip, Flávia De Angelis, Manuel Domine, Philip Clingan, Maximilian J Hochmair, Steven F Powell,[...]. N Engl J Med 2018
7

Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer.
Shirish Gadgeel, Delvys Rodríguez-Abreu, Giovanna Speranza, Emilio Esteban, Enriqueta Felip, Manuel Dómine, Rina Hui, Maximilian J Hochmair, Philip Clingan, Steven F Powell,[...]. J Clin Oncol 2020
269
7

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.
Mark A Socinski, Robert M Jotte, Federico Cappuzzo, Francisco Orlandi, Daniil Stroyakovskiy, Naoyuki Nogami, Delvys Rodríguez-Abreu, Denis Moro-Sibilot, Christian A Thomas, Fabrice Barlesi,[...]. N Engl J Med 2018
7

Toward personalized treatment approaches for non-small-cell lung cancer.
Meina Wang, Roy S Herbst, Chris Boshoff. Nat Med 2021
20
20

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.
Scott J Antonia, Augusto Villegas, Davey Daniel, David Vicente, Shuji Murakami, Rina Hui, Takayasu Kurata, Alberto Chiappori, Ki H Lee, Maike de Wit,[...]. N Engl J Med 2018
5

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.
Tony S K Mok, Yi-Long Wu, Iveta Kudaba, Dariusz M Kowalski, Byoung Chul Cho, Hande Z Turna, Gilberto Castro, Vichien Srimuninnimit, Konstantin K Laktionov, Igor Bondarenko,[...]. Lancet 2019
5

The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer.
Peter Goldstraw, Kari Chansky, John Crowley, Ramon Rami-Porta, Hisao Asamura, Wilfried E E Eberhardt, Andrew G Nicholson, Patti Groome, Alan Mitchell, Vanessa Bolejack. J Thorac Oncol 2016
5

Robust enumeration of cell subsets from tissue expression profiles.
Aaron M Newman, Chih Long Liu, Michael R Green, Andrew J Gentles, Weiguo Feng, Yue Xu, Chuong D Hoang, Maximilian Diehn, Ash A Alizadeh. Nat Methods 2015
5

Inferring tumour purity and stromal and immune cell admixture from expression data.
Kosuke Yoshihara, Maria Shahmoradgoli, Emmanuel Martínez, Rahulsimham Vegesna, Hoon Kim, Wandaliz Torres-Garcia, Victor Treviño, Hui Shen, Peter W Laird, Douglas A Levine,[...]. Nat Commun 2013
5

PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review.
Robert Brody, Yiduo Zhang, Marc Ballas, Mohd Kashif Siddiqui, Palvi Gupta, Craig Barker, Anita Midha, Jill Walker. Lung Cancer 2017
121
5

CD8+ cytotoxic T lymphocytes in cancer immunotherapy: A review.
Bagher Farhood, Masoud Najafi, Keywan Mortezaee. J Cell Physiol 2019
374
5

Non-small-cell lung cancer.
Cesare Gridelli, Antonio Rossi, David P Carbone, Juliana Guarize, Niki Karachaliou, Tony Mok, Francesco Petrella, Lorenzo Spaggiari, Rafael Rosell. Nat Rev Dis Primers 2015
319
5

Cancer Statistics, 2017.
Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal. CA Cancer J Clin 2017
5

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC.
Suresh S Ramalingam, Johan Vansteenkiste, David Planchard, Byoung Chul Cho, Jhanelle E Gray, Yuichiro Ohe, Caicun Zhou, Thanyanan Reungwetwattana, Ying Cheng, Busyamas Chewaskulyong,[...]. N Engl J Med 2020
716
5

Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.
Matthew D Hellmann, Luis Paz-Ares, Reyes Bernabe Caro, Bogdan Zurawski, Sang-We Kim, Enric Carcereny Costa, Keunchil Park, Aurelia Alexandru, Lorena Lupinacci, Emmanuel de la Mora Jimenez,[...]. N Engl J Med 2019
899
5

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial.
Luis Paz-Ares, Tudor-Eliade Ciuleanu, Manuel Cobo, Michael Schenker, Bogdan Zurawski, Juliana Menezes, Eduardo Richardet, Jaafar Bennouna, Enriqueta Felip, Oscar Juan-Vidal,[...]. Lancet Oncol 2021
197
5

Stereotactic Body Radiation Therapy for Operable Early-Stage Lung Cancer: Findings From the NRG Oncology RTOG 0618 Trial.
Robert D Timmerman, Rebecca Paulus, Harvey I Pass, Elizabeth M Gore, Martin J Edelman, James Galvin, William L Straube, Lucien A Nedzi, Ronald C McGarry, Cliff G Robinson,[...]. JAMA Oncol 2018
136
3

Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery.
Joe Y Chang, Reza J Mehran, Lei Feng, Vivek Verma, Zhongxing Liao, James W Welsh, Steven H Lin, Michael S O'Reilly, Melenda D Jeter, Peter A Balter,[...]. Lancet Oncol 2021
25
8

Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial.
Enriqueta Felip, Nasser Altorki, Caicun Zhou, Tibor Csőszi, Ihor Vynnychenko, Oleksandr Goloborodko, Alexander Luft, Andrey Akopov, Alex Martinez-Marti, Hirotsugu Kenmotsu,[...]. Lancet 2021
51
3

Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.
Jean-Pierre Pignon, Hélène Tribodet, Giorgio V Scagliotti, Jean-Yves Douillard, Frances A Shepherd, Richard J Stephens, Ariane Dunant, Valter Torri, Rafael Rosell, Lesley Seymour,[...]. J Clin Oncol 2008
3

Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.
Scott J Antonia, Augusto Villegas, Davey Daniel, David Vicente, Shuji Murakami, Rina Hui, Takashi Yokoi, Alberto Chiappori, Ki H Lee, Maike de Wit,[...]. N Engl J Med 2017
3

Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer.
Yi-Long Wu, Masahiro Tsuboi, Jie He, Thomas John, Christian Grohe, Margarita Majem, Jonathan W Goldman, Konstantin Laktionov, Sang-We Kim, Terufumi Kato,[...]. N Engl J Med 2020
316
3

Pembrolizumab for the treatment of non-small-cell lung cancer.
Edward B Garon, Naiyer A Rizvi, Rina Hui, Natasha Leighl, Ani S Balmanoukian, Joseph Paul Eder, Amita Patnaik, Charu Aggarwal, Matthew Gubens, Leora Horn,[...]. N Engl J Med 2015
3

A view on drug resistance in cancer.
Neil Vasan, José Baselga, David M Hyman. Nature 2019
456
3

Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial.
Harry J de Koning, Carlijn M van der Aalst, Pim A de Jong, Ernst T Scholten, Kristiaan Nackaerts, Marjolein A Heuvelmans, Jan-Willem J Lammers, Carla Weenink, Uraujh Yousaf-Khan, Nanda Horeweg,[...]. N Engl J Med 2020
708
3

Molecular testing and targeted therapy for non-small cell lung cancer: Current status and perspectives.
Evgeny N Imyanitov, Aglaya G Iyevleva, Evgeny V Levchenko. Crit Rev Oncol Hematol 2021
43
4

Management of non-small-cell lung cancer: recent developments.
Martin Reck, David F Heigener, Tony Mok, Jean-Charles Soria, Klaus F Rabe. Lancet 2013
537
3

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.
Achim Rittmeyer, Fabrice Barlesi, Daniel Waterkamp, Keunchil Park, Fortunato Ciardiello, Joachim von Pawel, Shirish M Gadgeel, Toyoaki Hida, Dariusz M Kowalski, Manuel Cobo Dols,[...]. Lancet 2017
3

PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy.
Sandip Pravin Patel, Razelle Kurzrock. Mol Cancer Ther 2015
3

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
Thomas J Lynch, Daphne W Bell, Raffaella Sordella, Sarada Gurubhagavatula, Ross A Okimoto, Brian W Brannigan, Patricia L Harris, Sara M Haserlat, Jeffrey G Supko, Frank G Haluska,[...]. N Engl J Med 2004
3

Regulation and Function of the PD-L1 Checkpoint.
Chong Sun, Riccardo Mezzadra, Ton N Schumacher. Immunity 2018
703
3

Microenvironmental regulation of tumor progression and metastasis.
Daniela F Quail, Johanna A Joyce. Nat Med 2013
3

Genomic landscape of lung adenocarcinoma in East Asians.
Jianbin Chen, Hechuan Yang, Audrey Su Min Teo, Lidyana Bte Amer, Faranak Ghazi Sherbaf, Chu Quan Tan, Jacob Josiah Santiago Alvarez, Bingxin Lu, Jia Qi Lim, Angela Takano,[...]. Nat Genet 2020
97
3

Abandoning the Notion of Non-Small Cell Lung Cancer.
Valeria Relli, Marco Trerotola, Emanuela Guerra, Saverio Alberti. Trends Mol Med 2019
59
3

Biomarkers for immune checkpoint inhibition in non-small cell lung cancer (NSCLC).
J Nicholas Bodor, Yanis Boumber, Hossein Borghaei. Cancer 2020
81
3

Tumor mutational load predicts survival after immunotherapy across multiple cancer types.
Robert M Samstein, Chung-Han Lee, Alexander N Shoushtari, Matthew D Hellmann, Ronglai Shen, Yelena Y Janjigian, David A Barron, Ahmet Zehir, Emmet J Jordan, Antonio Omuro,[...]. Nat Genet 2019
3

Nomograms in oncology: more than meets the eye.
Vinod P Balachandran, Mithat Gonen, J Joshua Smith, Ronald P DeMatteo. Lancet Oncol 2015
3

The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification.
William D Travis, Elisabeth Brambilla, Andrew G Nicholson, Yasushi Yatabe, John H M Austin, Mary Beth Beasley, Lucian R Chirieac, Sanja Dacic, Edwina Duhig, Douglas B Flieder,[...]. J Thorac Oncol 2015
3

NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021.
David S Ettinger, Douglas E Wood, Dara L Aisner, Wallace Akerley, Jessica R Bauman, Ankit Bharat, Debora S Bruno, Joe Y Chang, Lucian R Chirieac, Thomas A D'Amico,[...]. J Natl Compr Canc Netw 2021
134
3

Decision curve analysis: a novel method for evaluating prediction models.
Andrew J Vickers, Elena B Elkin. Med Decis Making 2006
3

High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden.
Ryma Benayed, Michael Offin, Kerry Mullaney, Purvil Sukhadia, Kelly Rios, Patrice Desmeules, Ryan Ptashkin, Helen Won, Jason Chang, Darragh Halpenny,[...]. Clin Cancer Res 2019
163
3

Lung cancer.
Richard D Neal, Fei Sun, Jon D Emery, Matthew E Callister. BMJ 2019
25
8

Targeting cancer-related inflammation in the era of immunotherapy.
Kyohei Nakamura, Mark J Smyth. Immunol Cell Biol 2017
95
3

Risk factors for lung cancer worldwide.
Jyoti Malhotra, Matteo Malvezzi, Eva Negri, Carlo La Vecchia, Paolo Boffetta. Eur Respir J 2016
225
3

Neutrophils in cancer: neutral no more.
Seth B Coffelt, Max D Wellenstein, Karin E de Visser. Nat Rev Cancer 2016
771
3

The biology and management of non-small cell lung cancer.
Roy S Herbst, Daniel Morgensztern, Chris Boshoff. Nature 2018
3


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.